Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey

• Published in: BMC cancer Vol. 18; no. 1; p. 1100
• Main Authors: Pigneux, Arnaud, Montesinos, Pau, Cong, Ze, Zhang, Xinke, Pownell, Anja K, Wieffer, Heather, McKendrick, Jan, Brüggemann, Monika
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.11.2018; BioMed Central; BMC
• Subjects: Acute lymphoblastic leukemia; Acute lymphocytic leukemia; Adult; Adults; ALL; Bone marrow; Cancer; Cancer screening; Cancer therapies; Care and treatment; Chemotherapy; Chromosomes; Clinical Decision-Making; Clinical medicine; Cross-Sectional Studies; Cross-sectional survey; Development and progression; Diagnosis; Europe - epidemiology; Female; Flow cytometry; Health Care Surveys; Hematology; Humans; Induction therapy; International aspects; Internet; Leukemia; Life Sciences; Lymphatic leukemia; Lymphocytes B; Male; Medical practice; Medical prognosis; Minimal residual disease; MRD testing; Neoplasm, Residual - diagnosis; Oncology; Patients; Pediatrics; Polls & surveys; Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology; Prognosis; Questionnaires; Recurrence (Disease); Remission; Risk factors; Stem cells; Studies; Surveys; Transplants & implants; Europe; Italy; United Kingdom > UK; France; Germany; Spain; Minimal residual disease; ALL; MRD testing; Cross-sectional survey

In acute lymphoblastic leukemia (ALL), the presence of minimal residual disease (MRD) after induction/consolidation chemotherapy is a strong prognostic factor for subsequent relapse and mortality. Accordingly, European clinical guidelines and protocols recommend testing patients who achieve a comple...